# Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy

> **NCT01061970** · PHASE2 · COMPLETED · sponsor: **QuatRx Pharmaceuticals Company** · enrollment: 15 (estimated)

## Conditions studied

- Hypogonadism
- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Fispemifene

## Key facts

- **NCT ID:** NCT01061970
- **Lead sponsor:** QuatRx Pharmaceuticals Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** —
- **Final completion:** 2007-10
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2010-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01061970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01061970, "Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01061970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*